Biosensor-Based Platforms for the Detection and Screening of <i>Mycobacterium leprae</i> Infection

Leprosy remains an important neglected tropical disease with about 200,000 new cases detected annually worldwide. Although the disease is highly responsive to treatment, a timely and accurate diagnosis continues to be a critical barrier to disease control. Traditional diagnostic methods, including PCR, bacilloscopy, histopathology, and serology, are hindered by limited sensitivity, procedural complexity, and restricted accessibility in resource-constrained settings. This review summarizes studies from the past decade on biosensor-based strategies for leprosy diagnosis. Biosensor platforms for leprosy include electrochemical, piezoelectric, and optical systems, with recent innovations encompassing immunosensors, biomimetic, and DNA-based approaches, some achieving diagnostic accuracies above 90%. These platforms employ different bioreceptors such as conjugated peptides, DNA probes, and molecularly imprinted polymers. Certain platforms can also differentiate paucibacillary from multibacillary cases, addressing a critical limitation of the current methods. These capabilities highlight the potential of biosensors as powerful tools for point-of-care testing. However, clinical translation is constrained by challenges such as affordability, robustness under field conditions, and the lack of large-scale validation studies. Additional operational barriers, including regulatory approval, supply chain logistics, and user training, must also be addressed. Future progress will depend on multidisciplinary strategies, integrating novel biomarker discovery as recognition elements and exploring detection systems previously used for other mycobacterial and infectious diseases. Large multicenter trials and user-centered design approaches are essential for clinical implementation. By overcoming these challenges, biosensors have the potential to redefine leprosy diagnostics, enabling earlier detection and improved surveillance, and accelerating progress toward global elimination goals.

Authors

Institutions

Publication Details

Journal
ACS Infectious Diseases
Published
2026-01-21
DOI
https://doi.org/10.1021/acsinfecdis.5c00851
Primary Topic
Leprosy Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biosensor-Based Platforms for the Detection and Screening of Mycobacterium leprae Infection

Augusto César Parreiras de Jesus, Cristiane Alves da Silva Menezes, Thomas J. Cleij, Bart van Grinsven et al.
ACS Infectious Diseases
Leprosy Research and Treatment
article

Biosensor-Based Platforms for the Detection and Screening of Mycobacterium leprae Infection

Augusto César Parreiras de Jesus, Cristiane Alves da Silva Menezes, Thomas J. Cleij, Bart van Grinsven, Rocio Arreguin-Campos, Flavia Di Scala, Lilian Lacerda Bueno, Ricardo Toshio Fujiwara, Ana Laura Grossi de Oliveira
article en

Abstract

Leprosy remains an important neglected tropical disease with about 200,000 new cases detected annually worldwide. Although the disease is highly responsive to treatment, a timely and accurate diagnosis continues to be a critical barrier to disease control. Traditional diagnostic methods, including PCR, bacilloscopy, histopathology, and serology, are hindered by limited sensitivity, procedural complexity, and restricted accessibility in resource-constrained settings. This review summarizes studies from the past decade on biosensor-based strategies for leprosy diagnosis. Biosensor platforms for leprosy include electrochemical, piezoelectric, and optical systems, with recent innovations encompassing immunosensors, biomimetic, and DNA-based approaches, some achieving diagnostic accuracies above 90%. These platforms employ different bioreceptors such as conjugated peptides, DNA probes, and molecularly imprinted polymers. Certain platforms can also differentiate paucibacillary from multibacillary cases, addressing a critical limitation of the current methods. These capabilities highlight the potential of biosensors as powerful tools for point-of-care testing. However, clinical translation is constrained by challenges such as affordability, robustness under field conditions, and the lack of large-scale validation studies. Additional operational barriers, including regulatory approval, supply chain logistics, and user training, must also be addressed. Future progress will depend on multidisciplinary strategies, integrating novel biomarker discovery as recognition elements and exploring detection systems previously used for other mycobacterial and infectious diseases. Large multicenter trials and user-centered design approaches are essential for clinical implementation. By overcoming these challenges, biosensors have the potential to redefine leprosy diagnostics, enabling earlier detection and improved surveillance, and accelerating progress toward global elimination goals.

ACS Infectious DiseasesVol. 12(2)
Universidade Federal de Minas Gerais (BR), Maastricht School of Management (NL), Maastricht University (NL)
Openalex Percentile: Top 81%
Leprosy Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.